These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24760401)

  • 1. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
    Braeckman RA; Stirtan WG; Soni PN
    Clin Drug Investig; 2014 Jul; 34(7):449-56. PubMed ID: 24760401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
    Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
    Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
    Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.
    Braeckman RA; Stirtan WG; Soni PN
    Drugs R D; 2014 Sep; 14(3):159-64. PubMed ID: 24973042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
    Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.
    Braeckman RA; Stirtan WG; Soni PN
    Clin Drug Investig; 2015 Jan; 35(1):45-51. PubMed ID: 25471740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers.
    Offman E; Davidson M; Nilsson C
    Am J Cardiovasc Drugs; 2017 Jun; 17(3):251-260. PubMed ID: 28197979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G; Mandagere A; Dufton C; Venitz J
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
    Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
    Weiss D; Knight R; Zhou S; Palmisano M; Chen N
    Clin Drug Investig; 2015 Jul; 35(7):455-61. PubMed ID: 26024727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
    Salem AH; Hu B; Freise KJ; Agarwal SK; Sidhu DS; Wong SL
    Clin Drug Investig; 2017 Mar; 37(3):303-309. PubMed ID: 27910036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Almeida L; Falcão A; Vaz-da-Silva M; Nunes T; Santos AT; Rocha JF; Neta C; Macedo T; Fontes-Ribeiro C; Soares-da-Silva P
    Eur J Clin Pharmacol; 2008 Oct; 64(10):961-6. PubMed ID: 18679669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
    Wu JC; Nafziger AN; Bertino JS; Ma JD
    Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
    Chang AT; Bertino JS; Nafziger AN; Kashuba AD; Turpault S; Lewis LD; Ma JD
    Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.